Roche’s Onartuzumab Failure Raises More Questions About How Best To Target Met
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche’s onartuzumab (MetMab) fails in Phase III lung cancer study, raising questions about the company’s biomarker approach and the Met target more generally.
You may also be interested in...
ArQule Pleads Tivantinib’s Promise In Liver Cancer After Lung Cancer Blow-up
Progression-free survival benefit fails to translate into overall survival in Phase III NSCLC study of c-Met inhibitor tivantinib, partnered with Daiichi Sankyo. ArQule shifts focus to an imminent, targeted second-line Phase III study of high-Met expressing hepatocellular cancer.
Roche's Diagnostic Foothold Gives Genentech A Leg Up In Oncology
Research to be presented at American Society of Clinical Oncology meeting shows role of biomarkers for lead compounds, including vemurafenib, MetMAb and Tarceva.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.